BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

nork Cabanillas, M. E., Patel, A., Danysh, B. P., Dadu, R., Kopetz, S., Falchook, G.
Argitaratua izan da Horm Cancer (2014)

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer(†)

nork Falchook, G. S., Moulder, S. L., Wheler, J. J., Jiang, Y., Bastida, C. C., Kurzrock, R.
Argitaratua 2013

Age-Stratified Phase I Trial of a Combination of Bortezomib, Gemcitabine, and Liposomal Doxorubicin in Patients with Advanced Malignancies

nork Falchook, G. S., Duvic, M., Hong, D. S., Wheler, J., Naing, A., Lim, J., Kurzrock, R.
Argitaratua 2011

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience

nork Wheler, J. J., Tsimberidou, A. M., Hong, D. S., Naing, A., Falchook, G. S., Fu, S., Moulder, S., Stephen, B., Wen, S., Kurzrock, R.
Argitaratua 2012

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

nork Falchook, G.S., Trent, J.C., Heinrich, M.C, Beadling, C., Patterson, J., Bastida, C.C., Blackman, S.C., Kurzrock, R.
Argitaratua 2013

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment

nork Falchook, G. S., Vega, F., Dang, N. H., Samaniego, F., Rodriguez, M. A., Champlin, R. E., Hosing, C., Verstovsek, S., Pro, B.
Argitaratua 2009

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy

nork Wheler, J. J., Falchook, G. S., Tsimberidou, A. M., Hong, D. S., Naing, A., Piha-Paul, S. A., Chen, S. S., Fu, S., Stephen, B., Fok, J. Y., Janku, F., Kurzrock, R.
Argitaratua 2013

The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials

nork Said, R., Banchs, J., Wheler, J., Hess, K. R., Falchook, G., Fu, S., Naing, A., Hong, D., Piha-Paul, S., Ye, Y., Yeh, E., Wolff, R. A., Tsimberidou, A. M.
Argitaratua 2014

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes

nork Henary, H., Hong, D. S., Falchook, G. S., Tsimberidou, A., George, G. C., Wen, S., Wheler, J., Fu, S., Naing, A., Piha-Paul, S., Janku, F., Kim, K. B., Hwu, P., Kurzrock, R.
Argitaratua 2013

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs

nork Naing, A., Veasey-Rodrigues, H., Hong, D. S., Fu, S., Falchook, G. S., Wheler, J. J., Tsimberidou, A. M., Wen, S., Fessahaye, S. N., Golden, E. C., Aaron, J., Ewer, M. S., Kurzrock, R.
Argitaratua 2012

RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers

nork Falchook, G.S., Long, G.V., Kurzrock, R., Kim, K.B., Arkenau, H.T., Brown, M.P., Hamid, O., Infante, J.R., Millward, M., Pavlick, A., O’Day, S.J., Blackman, S.C., Curtis, C.M., Lebowitz, P., Ma, B., Ouellet, D., Kefford, R.F.
Argitaratua 2012

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

nork Liu, X., George, G. C., Tsimberidou, A. M., Naing, A., Wheler, J. J., Kopetz, S., Fu, S., Piha-Paul, S. A., Eng, C., Falchook, G. S., Janku, F., Garrett, C., Karp, D., Kurzrock, R., Zinner, R., Raghav, K., Subbiah, V., Hess, K., Meric-Bernstam, F., Hong, D. S., Overman, M. J.
Argitaratua izan da BMC Cancer (2015)

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

nork Cascone, T., Sacks, R.L., Subbiah, I.M., Drobnitzky, N., Piha-Paul, S.A., Hong, D.S., Hess, K.R., Amini, B., Bhatt, T., Fu, S., Naing, A., Janku, F., Karp, D., Falchook, G.S., Conley, A.P., Sherman, S.I., Meric-Bernstam, F., Ryan, A.J., Heymach, J.V., Subbiah, V.
Argitaratua izan da ESMO Open (2021)

KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors

nork Hong, D.S., Fakih, M.G., Strickler, J.H., Desai, J., Durm, G.A., Shapiro, G.I., Falchook, G.S., Price, T.J., Sacher, A., Denlinger, C.S., Bang, Y.-J., Dy, G.K., Krauss, J.C., Kuboki, Y., Kuo, J.C., Coveler, A.L., Park, K., Kim, T.W., Barlesi, F., Munster, P.N., Ramalingam, S.S., Burns, T.F., Meric-Bernstam, F., Henary, H., Ngang, J., Ngarmchamnanrith, G., Kim, J., Houk, B.E., Canon, J., Lipford, J.R., Friberg, G., Lito, P., Govindan, R., Li, B.T.
Argitaratua izan da N Engl J Med (2020)